Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E

This study has been completed.

First Received: September 26, 2008 Last Updated: October 20, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00761501

Purpose

The purpose of the study is to investigate the uptake in the body of naproxen; one of the two active substances in PN400. We also want to show that the body's uptake of naproxen given as PN400 is comparable to that of currently marketed naproxen tablets.

Condition	Intervention	Phase
Healthy Volunteer	Drug: PN4000 Drug: Naproxen (Proxen S) Drug: Naproxen (Naprosyn E)	Phase I

Study Type:	Interventional
Study Design:	Randomized, Open Label, Crossover Assignment, Bio-availability Study
Official Title:	Phase I, Open-label, Randomized, 3-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers

Resource links provided by NLM:

Drug Information available for: Naproxen Naproxen sodium

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Pharmacokinetics [ Time Frame: pre-dose and multiple times post-dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Safety [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	38
Study Start Date:	September 2008
Study Completion Date:	December 2008
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: PN4000 Oral
2: Active Comparator	Drug: Naproxen (Proxen S) Oral
3: Active Comparator	Drug: Naproxen (Naprosyn E) Oral

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Body Mass Index (BMI) of greater than or equal to 19 to less than or equal to 30 kg/m2 and weight of greater than or equal to 50 to less than or equal to 100 kg
Clinically normal physical exams and laboratory measurements

Exclusion Criteria:

Subject has received another investigational drug within 4 weeks preceding this study or planning to participate in another study at any time during the period of this study
Any significant medical or psychiatric condition that could affect the interpretation of the PK data, or which otherwise would contraindicate participation in a clinical trial
Any GI disease, abnormality or gastric surgery that may interfere with gastric emptying, motility and drug absorption
Subject who has donated a unit of blood or plasma within 3 months prior to the Screening Visit

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00761501

Locations

Sweden
Research Site
Uppsala, Sweden
Research Site
Lulea, Sweden

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Mark Sostek, MD	AstraZeneca
Principal Investigator:	Aslak Rautio, MD	Quintiles Hermelinen
Principal Investigator:	Wolfgang Kuhn, MD	Quintiles Phase I Services

More Information

No publications provided

Responsible Party:	AstraZeneca Pharmaceuticals ( Mark Sostek, MD, Medical Science Director, Development Projects )
Study ID Numbers:	D1120C00001
Study First Received:	September 26, 2008
Last Updated:	October 20, 2009
ClinicalTrials.gov Identifier:	NCT00761501 History of Changes
Health Authority:	Sweden: Medical Products Agency

Keywords provided by AstraZeneca:

Phase I
Healthy Volunteer

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Naproxen
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Pharmacologic Actions

Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010